You just read:

Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)

News provided by

Viking Therapeutics, Inc.

Oct 04, 2017, 07:05 ET